• Molecular NameNitrofurantoin
  • SynonymNA
  • Weight238.159
  • Drugbank_IDDB00698
  • ACS_NO67-20-9
  • Show 3D model
  • LogP (experiment)-0.5
  • LogP (predicted, AB/LogP v2.0)0.22
  • pka7.2
  • LogD (pH=7, predicted)0.04
  • Solubility (experiment)0.0795 mg/ml
  • LogS (predicted, ACD/Labs)(ph=7)-3.66
  • LogSw (predicted, AB/LogsW2.0)0.25
  • Sw (mg/ml) (predicted, ACD/Labs)0.04
  • No.of HBond Donors1
  • No.of HBond Acceptors9
  • No.of Rotatable Bonds3
  • TPSA123.74
  • StatusFDA approved
  • Administrationoral, rectal
  • PharmacologyIt is usually used in treating urinary tract infection. Like many other drugs, it is often used against E Coli.
  • Absorption_value95.0
  • Absorption (description)N/A
  • Caco_2N/A
  • Bioavailability87.0
  • Protein binding62.0
  • Volume of distribution (VD)0.58 L/kg
  • Blood/Plasma Partitioning ratio (D_blood)N/A
  • Metabollsmliver (75%)
  • Half life1.0 h
  • Excretionurine and bile
  • Urinary Excretion47
  • Clerance9.9
  • ToxicityIn clinical trials of Nitrofurantoin, the most frequent clinical adverse events that were reported as possibly or probably drug-related were nausea (8%), headache (6%), and flatulence (1.5%).
  • LD50 (rat)N/A
  • LD50 (mouse)N/A